Utility of Head and Neck Cutaneous Squamous Cell Carcinoma Sentinel Node Biopsy

Abstract

Objective

Sentinel lymph node biopsy (SLNB) is standard of care for melanoma, but its role in cutaneous squamous cell carcinoma (cSCC) has not been established. Study objectives include: (1) analyze the feasibility and reliability SLNB for head and neck (H&N) cSCC and (2) identify risk factors associated with a positive SLN.

Data Sources

MEDLINE, PubMed, Cochrane, and ASCO databases searches conducted (1946-2013).

Review Methods

Using the PRISM model, a comprehensive systematic review of H&N cSCC SLNB studies with associated recurrence rates was conducted. Dual-blinded data extraction identify primary outcomes (successful SLN harvest and false omission rate) and secondary outcomes (risk factors associated with a +SLN).

Results

Two hundred twenty-one articles were screened; 73 patients from 11 publications met inclusion criteria (3 case series; 8 prospective cohorts). Studies ranged from 1 to 15 patients (median 5). Median age was 74 years. Median follow-up was 21.5 months. Average tumor size was 3.09 cm. At least 1 SLN was identified in 100% of patients (median 2). Ten (13.5%) had a positive SLN; no additional metastatic nodes were identified in 9 patients receiving completion lymphadenectomy. Tumor diameter was not associated with SLN status (P = .09; 95% CI, –.27 to 3.02). Risk factors (tumor depth, perineural invasion, location, differentiation) were not consistently recorded. Three of 63 (4.76%) failed regionally following a negative SLNB.

Conclusion

H&N cSCC SLNB is feasible and reliable for staging, with a false omission rate of 4.7% mirroring melanoma. Prospective studies documenting high risk features are required to further define its role.

Keywords

sentinel node cutaneous squamous cell carcinoma skin cancer

Get full access to this article

View all access options for this article.

References

Karia

Han

Schmults

. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and death from disease in the United States, 2012. J Am Acad Dermatol. 2013;68:957-966.

Johnson

Rowe

Nelson

Swanson

. Squamous cell carcinoma of the skin (excluding lip and oral muscoa). J Am Acad Dermatol. 1992;26:467-484.

Kraus

Carew

Harrison

. Regional lymphnode metastasis from cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1998;124:582-587.

Choi

Lazovich

Southwell

Forster

Rolnick

Jackson

. Prevalence and characteristics of indoor tanning use in America among men and women. Arch Dermatol. 2010;146:1356-1361.

Rowe

Caroll

Day

Jr . Prognostic factors for local recurrence, metastasis and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976-990.

Berg

. Screening for Skin Cancer. US Preventive Services Task Force; 2007.

O’Brien

McNeil

McMahon

. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck. 2002;24:417-422.

Wagner

Evdokimow

Weisberger

. Sentinel node biopsy for high-risk nonmelanoma cutaneous malignancy. Arch Dermatol. 2004;140:75-79.

Schmalbach

Nussenbaum

Rees

Schwartz

Johnson

Bradford

. Reliability of sentinel lymph node mapping with biopsy for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg. 2003;129:61-65.

10.

Alex

. The application of sentinel node radiolocalization to solid tumors of the head and neck: a 10-year experience. Laryngoscope. 2004;114:2-19.

11.

National Comprehensive Cancer Network (NCCN)clinical practice guidelines in oncology: melanoma. V.2.2013. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Retrieved July 1, 2013.

12.

Michl

Starz

Bachter

Balda

. Sentinel lymphonodectomy in nonmelanoma skin malignancies. Br J Dermatol. 2003;149:763-769.

13.

Reschly

Messina

Zaulyanov

Cruse

Fenske

. Utility of sentinel lymphadenectomy in the management of patients with high-risk cutaneous squamous cell carcinoma. Dermatol Surg. 2003;29:135-140.

14.

Nouri

Rivas

Pedroso

Bhatia

Civantos

. Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma of the head and neck. Arch Dermatol. 2004;140:1284.

15.

Cecchi

Buralli

De Gaudio

. Lymphatic mapping and sentinel lymphonodectomy in recurrent cutaneous squamous cell carcinoma. Eur J Dermatol. 2005;15:478-479.

16.

Civantos

Moffat

Goodwin

. Lymphatic mapping and sentinel lymphadenectomy for 106 head and neck lesions: contrasts between oral cavity and cutaneous malignancy. Laryngoscope. 2006;116(suppl. 109):1-15.

17.

Shan

Lang

. Sentinel lymph node biopsy for high-risk nonmelanoma skin cancers. Dermatol Surg. 2007;33:789-794.

18.

Resendiz-Xolosia

Valenzuela-Flores

Torres-Nunez

. Mapeo linfatico y biopsia del ganglio centinela en pacientes con carcinoma epidermoide cutaneo dealto riesgo. Gac Med Mex. 2007;143:209-214.

19.

Rastrelli

Soteldo

Zonta

. Sentinel node biopsy for high-risk cutaneous nonanogential squamous cell carcinoma: a preliminary result. Eur Surg Res. 2010;44:204-208.

20.

Kwon

Dong

. Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: clinical experience and review of literature. World J Surg Oncol. 2011;9:80-87.

21.

Demir

Isken

Kus

. Sentinel lymph node biopsy with a gamma probe in patients with high-risk cutaneous squamous cell carcinoma: follow-up results of sentinel lymph node-negative patients. Nucl Med Commun. 2011;32:1215-1222.

22.

Moher

Liberati

Tetzlaff

Altman

. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.

23.

Liberati

Altman

Tetzlaff

. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ. 2009;339:b2700.

24.

Slim

Nini

Forestier

Kwiatkowski

Panis

Chipponi

. Methodological index for non-randomized studies (MINORS): development and validation of a new statement. ANZ J Surg. 2003;73:712-716.

25.

Erman

Collar

Griffith

. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer. 2012;118:1040-1047.

26.

Ross

Schmults

. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg. 2006;32:1309-1321.

27.

Renzi

Caggiati

Mannooranparampil

. Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: case series and review of the literature. Eur J Surg Oncol. 2007;3:364-369.

28.

Martinez

Cook

. High-risk cutaneous squamous cell carcinoma without palpable lymphadenopathy: is there a therapeutic role for elective neck dissection. Dermatol Surg. 2007;33:410-420.

29.

De Rosa

Lyman

Silbermins

. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg. 2011;145:375-382.

30.

Morton

Thompson

Cochran

. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317. Erratum in: N Engl J Med. 2006;355:1944.

31.

Cascinelli

Belli

Santinami

. Sentine lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol. 2000;7:469.

32.

Farast

Neel

. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64:1051-1059.

33.

Gershenwald

Tseng

Thompson

. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998;124:203-210.

34.

Vermeeren

Valdés Olmos

Klop

. SPECT/CT for sentinel lymph node mapping for head and neck melanoma. Head Neck. 2011;33:1-6.

35.

Weisberg

Bertagnolli

Becker

. Combined sentinel lymphagenectomy and Mohs micrographic surgery for high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2000;43:483-488.